A supplemental new drug application for zanubrutinib (Brukinsa) as therapy for patients with marginal zone lymphoma (MZL) who have received 1 or more prior anti-CD20–based therapies was accepted and granted priority review by the FDA, according to the company responsible for developing the agent, Beigene, Ltd.1 The data supporting the Read more…
Long-term 20-year follow-up of premenopausal patients with oestrogen receptor (ER)-positive breast cancer and stratification by the 70-gene Risk Signature suggested that patients at high risk of distant disease recurrence derive significant benefit from goserelin, while patients at low risk have greater benefit with tamoxifen. These findings were presented at the ESMO Read more…
Multiple studies have shown that African American women with breast cancer have lower survival rates than white women with the disease. But the association between race or ethnicity and treatment outcomes in triple-negative breast cancer — an aggressive type of tumor that does not respond to hormonal or other targeted Read more…
The Institute for Clinical and Economic Review (ICER) today released a Final Evidence Report assessing the comparative clinical effectiveness and value of three new treatments targeting the B-cell maturation antigen (BCMA) for heavily pre-treated patients with triple class refractory multiple myeloma (TCRMM) who have cycled through numerous previous lines of therapy: idecabtagene Read more…
New data from Daiichi Sankyo Company, Limited (hereafter, Daiichi Sankyo) and AstraZeneca’s datopotamab deruxtecan (Dato-DXd), a TROP2 directed DXd antibody drug conjugate (ADC), showed preliminary response and disease control in patients with metastatic triple negative breast cancer (TNBC) with disease progression following standard treatment. These preliminary data from the TNBC Read more…
More than two-thirds of pancreatic cancer patients harboring genetic mutations saw their tumor stop growing or shrink substantially after being switched from intensive chemotherapy to the PARP inhibitor rucaparib as a maintenance therapy, researchers from the Abramson Cancer Center at the University of Pennsylvania reported online today in the Journal of Clinical Oncology. Read more…
In this Phase 3 trial, Libtayo demonstrated a significant improvement in overall survival in women with advanced cervical cancer after progression on chemotherapy, reducing the risk of death by 31% compared to chemotherapy in the overall population,” said Krishnansu S. Tewari, M.D., Professor and Director of the Division of Gynecologic Oncology at the University Read more…
KENILWORTH, N.J.–(BUSINESS WIRE)– Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced positive results from the pivotal neoadjuvant/adjuvant Phase 3 KEYNOTE-522 trial investigating KEYTRUDA, Merck’s anti-PD-1 therapy, in combination with chemotherapy as pre-operative (neoadjuvant) treatment and then continuing as a single agent (adjuvant) treatment after Read more…
A systematic review and meta-analysis published in JAMA Dermatology identified a potential link between topical calcineurin inhibitors (TCIs) and an increased risk for lymphoma. However, the association did not extend to other forms of cancer, and the absolute risk for lymphoma among users of TCIs remained low. TCIs are used frequently as Read more…
The FDA approved TheraSphere Y-90 Glass Microspheres, a radioembolization technology, for the treatment of patients with hepatocellular carcinoma (HCC), according to a press release. The therapy was previously granted humanitarian device exemption, which limited the number of patients treated with the therapy per year. The technology is a type of selective internal Read more…